These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19226677)

  • 21. Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy.
    De Socio GV; Martinelli L; Zazzi M; Baldelli F
    Clin Infect Dis; 2008 Jun; 46(12):1938. PubMed ID: 18540815
    [No Abstract]   [Full Text] [Related]  

  • 22. ABT-378 lowers viral load.
    AIDS Patient Care STDS; 1999 Mar; 13(3):199. PubMed ID: 10375268
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination drug approved to treat HIV.
    FDA Consum; 2001; 35(1):5. PubMed ID: 11930926
    [No Abstract]   [Full Text] [Related]  

  • 24. Kaletra: applying advances in pharmacokinetics to treating HIV.
    Edmunds-Ogbuokiri J
    HIV Clin; 2001; 13(1):8-9. PubMed ID: 11810818
    [No Abstract]   [Full Text] [Related]  

  • 25. Better lipid profile for Invirase.
    AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17216875
    [No Abstract]   [Full Text] [Related]  

  • 26. Once-daily Kaletra approved.
    AIDS Patient Care STDS; 2005 Jul; 19(7):467. PubMed ID: 16053404
    [No Abstract]   [Full Text] [Related]  

  • 27. Reyataz monotherapy study stopped.
    Proj Inf Perspect; 2007 Oct; (44):23-4. PubMed ID: 18046835
    [No Abstract]   [Full Text] [Related]  

  • 28. Ugandan children receive lower-strength Aluvia.
    AIDS Patient Care STDS; 2008 Jan; 22(1):86-7. PubMed ID: 18453040
    [No Abstract]   [Full Text] [Related]  

  • 29. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacologic interest in HIV protease inhibitors: concepts and utilization].
    Peytavin G
    Med Mal Infect; 2006 Jul; 36 Suppl 2():S191-7. PubMed ID: 17075996
    [No Abstract]   [Full Text] [Related]  

  • 31. Plotting the perfect protease inhibitor.
    Huff B
    GMHC Treat Issues; 2005; 19(1-2):15. PubMed ID: 15841539
    [No Abstract]   [Full Text] [Related]  

  • 32. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load.
    Pasquet A; Ajana F; Melliez H; Giurca C; Poissy J; Yazdanpanah Y
    AIDS; 2012 Aug; 26(13):1726-8. PubMed ID: 22874480
    [No Abstract]   [Full Text] [Related]  

  • 33. Abbott expands low cost Kaletra.
    AIDS Patient Care STDS; 2006 Oct; 20(10):731-2. PubMed ID: 17083155
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
    Flandre P; Delaugerre C; Ghosn J; Chaix ML; Horban A; Girard PM; Gladysz A; Cohen-Codar I; Van PN; Taburet AM; Rouzioux C; Delfraissy JF;
    Antivir Ther; 2009; 14(1):93-7. PubMed ID: 19320241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kaletra (ABT-378/r) application for accelerated approval.
    AIDS Treat News; 2000 Jun; (345):2-3. PubMed ID: 12170977
    [No Abstract]   [Full Text] [Related]  

  • 36. [Kaletra, a new anti HIV agent].
    Taéron C
    Rev Infirm; 2006 Dec; (126):41-2. PubMed ID: 17269306
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
    L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
    AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands.
    Goossens VJ; Wolffs PF; van Loo IH; Bruggeman CA; Verbon A
    AIDS; 2009 Jul; 23(11):1425-9. PubMed ID: 19531930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.